tasly compound danshen dripping pill dispute closed five years Rashomon door difficult to end

Compound danshen dripping pill dispute closed five years "Rashomon door" difficult to break Wang Weijia five years of dispute, once closed. September 15, tasly (600535.SH) issued "on the Chinese Academy of Engineering Li Lianda pharmacologist infringement of the right to honor the company's reputation," announced the Supreme People's Court in Tianjin this month to make the final judgment-judgment tasly win; The Li Lianda pharmacologist of the question of compound danshen dripping pill was asked to stop making comments, apologized to tasly and compensated for the economic loss of 300,000 yuan. So far, since 2009, a 5-year "controversy" over the safety of compound danshen dripping pills around tasly has come to an ending. But could the 5-year dispute between Tasly and the 80-year-old Li Lianda pharmacologist really be settled with a court decision? "Rashomon Gate" February 2009, Li Lianda pharmacologist through the paper publicly pointed out that by tasly production of compound danshen dripping pill adverse reaction rate of up to 3.1%, and tasly company did not do long-term toxicity test-as the tasly of the household products, compound danshen dripping pill in 2009 sales have been close to 1 billion yuan, The most important product of the tasly was then successfully entered into the National health insurance, the national basic drugs and the national base drug low-cost drugs catalogue. According to Li Lianda Pharmacologist released at the time, a study conducted in the first half of 2008 showed that tasly's main product compound danshen dripping pill has low effective ingredient, adverse reaction rate of 3.1% and no long-term toxicity test, can cause gastrointestinal reaction, shock, blood and other adverse reactions. According to Li Lianda Pharmacologist's suggestion, because the compound danshen dripping pill needs to be taken for a long time, its adverse drug reactions need to be paid particular attention to-"Therefore, the study of this drug, how serious the toxicity, this information is not enough, we do not find tasly in this area of work." Li Lianda pharmacologist at that time made public the conclusion of its public. After the publication of this conclusion, according to Tasly, "as an academician of the Academy of Engineering and the authority of the Chinese Medicine academia, Li Lianda pharmacologist to tasly core products of compound danshen dripping pill caused a great uproar, a time people have a serious psychological panic, leading to tasly stock prices plummeted or even forced to suspend a series of chain reaction "" 2009 we decided to sue him, prudent, we hired several civil law experts for certification, and later this matter to the relevant industry associations and leadership reporting, leadership to coordinate, I hope we do not litigation to the law, our company after the internal collegiate, did not bring a lawsuit. "Tasly Holding Group Co., Ltd. legal director Zheng, said in an interview with the first financial daily. In five years, although the two sides have had many mediation, but Zheng said, Li Lianda pharmacologist did not stop to publish the relevant remarks, but, tasly side finally chose the legal action. The dust is flat. However, Li Lianda pharmacologist does not agree with this statement. "Shing (Chairman of tasly Board) in chief editor of" Radix salviae miltiorrhizae "5 volumes 255 pages, reported 5169 cases of 161 patients with adverse reactions, accounting for 3.11%. Among them dizziness head expands face red 100 cases, gastrointestinal tract antiIn 51 cases, blood pressure increased 1 cases, rash 1 cases, fainting 2 cases, shock 1 cases, hematuria 1 cases, gastric mucosa erosion edema, bleeding and pyloric deformation 2 cases and other adverse reactions. These content and the data is the Yan always writes in the book, is not others to fabricate. The book that oneself writes, oneself do not admit, Fanwu is others fabricate, what reason? --September 11, after the Tianjin High Court to make a ruling, Li Lianda pharmacologist through the Science network published "The key to the controversy of the adverse reaction of compound danshen dripping pill", and this is also since the September 1 final defeat, Li Lianda pharmacologist again openly questioned the tasly compound danshen dripping pill adverse reaction problem. Also in this public article, which is once again challenged, Li Lianda pharmacologist pointed out: "The National Food and Drug Administration 2012 national Adverse reaction Monitoring Annual report" Clearly pointed out: "National essential drugs" in Chinese medicine orally, the most adverse reaction cases, the second is the compound Danshen preparation (including four kinds of dosage forms). It was confirmed that the drug had adverse reactions and was second highest. This is the authoritative conclusion issued by the State authority, not by anyone. "And for the 300,000 Yuan compensation tasly due to the loss of reputation caused by price fluctuations, Li Lianda pharmacologist said:" According to the overall evidence of Yan, in my February 5, 2009 criticism of the drug adverse reaction, February 3, 4th, shares have fallen, only February 4 fell 2.74%, and in my February 5 criticism, the day by 2.74 The rise of% to-2.63%, the increase of 1.04% on February 9, and the increase of 1.32% on February 10, by 2.98% per cent on February 6, indicate that my criticisms of the adverse reaction of the drug have not led to a fall in the share price. It is irrelevant to my criticism that the price fluctuation is the result of many factors. After the publication of the article on the fourth day, Tasly issued a clarification announcement of the court decision, alleged Li Lianda pharmacologist no scientific basis and factual basis of the speech disparaging belittle the company's main products compound danshen dripping pill, seriously damaging the company and the company's products good image and reputation, infringing the company's reputation and economic interests. Although Li Lianda pharmacologist refused to interview, but September 22, its personal blog issued a statement: "The people's eyes are discerning"; "Aboveboard, Phitan, Kang, defying dignitaries, dare to tell the truth, dare to speak out, dare to see the uneven roar of the road, is my life's pursuit." Never waver. "The breed dispute in fact, the compound danshen dripping pill has been considered as the first fruit of Chinese Traditional medicine modernization and internationalization. 1997, the State put forward the "modernization of traditional Chinese medicine development strategy", in the national selection of traditional Chinese medicine varieties, as drug status to the FDA declaration, the compound danshen dripping pill was selected as the first case of China through the approval of the compound Chinese medicine preparation. January 2010, the compound danshen dripping pill in the United States completed Ⅱ period of clinical practice; August 12, 2012, the clinical Ⅲ trial of compound danshen dripping pill was officially initiated by FDA, according to FDA documents, the goal of clinical Ⅲ period is to confirm the effect of the product on angina pectoris of patients with stable angina pectoris, it is estimated that 960 The expected finish date isAugust 2015. According to the drug listing process, a clinical Ⅲ trial must be passed before the drug is listed-which means if the compound danshen dripping pill is able to go through the last clinical trial before August, it will not only sell in the United States, but also greatly boost the status and market performance of this breed in the Chinese domestic market with high cardiovascular disease. Public data show that the compound danshen dripping pill is the most important variety of tasly, the current sales have more than 2 billion yuan, in the cardiovascular market, the share of about 15%, the past three years of composite sales growth rate of more than 15%. And with the enmity between Li Lianda pharmacologist and Tasly, another listed company wide drug was again involved. 2009, when tasly general manager of Levin had to the media blunt, Li Lianda pharmacologist in addition to academician status, or competitors, the largest domestic compound Danshen production Enterprise chief scientist, it is believed that Li Lianda pharmacologist represents the benefits of compound Danshen tablets. Public data show, Li Lianda pharmacologist has said to the media: "One is the result of the comparison of compound danshen dripping pill, this drop pill, is the drop pill produced by Tianjin tasly ... The effect of dripping pills is poor, better than tablets ... "coincidentally, Canton Pharmaceutical Group's Guangzhou Baiyun Mountain, Hutchison Chinese Medicine Co., Ltd. produced varieties of compound Danshen tablets. Yesterday, on the above related issues, Canton Pharmaceutical Group did not make any reply to this newspaper.